Shanton Pharma Meets Primary Endpoint for Phase 2 Study of SAP-001

The Shanton Pharma Phase 2 study evaluating its investigational product SAP-001, an oral, small molecule, achieved its primary endpoint. In the trial, SAP-001 significantly reduce uric acid . SAP-001 was well tolerated.

The release as fetched from its publisher. shantonpharma.com ↗